Skip to content
Search

Latest Stories

New anti-smoking pill ‘Varenicline’ to help save NHS millions

New anti-smoking pill ‘Varenicline’ to help save NHS millions

The daily pill, made available through NHS stop smoking services, has been shown  to be more effective than nicotine replacement gum or patches

Tens of thousands of smokers in England will be offered an improved anti-smoking pill by the NHS to help them quit.

NHS England has announced the rollout of a new generic version of Champix, called Varenicline, which has been proven to be as effective as vapes and more successful than nicotine replacement gum or patches.


When used alongside behavioural support, such as counselling, the daily pill has been shown to help one in four smokers quit for at least six months.

NHS chief executive Amanda Pritchard called the introduction of Varenicline a “vital step in shifting NHS further towards prevention” and highlighted that it could be a “game-changer” for people who want to quit smoking.

Speaking at the NHS Providers annual conference in Liverpool on Tuesday, she emphasised that smoking remains “one of the biggest public health issues facing the NHS.”

“Alongside supporting the government’s ambition to create the first smoke-free generation, we are giving current smokers the tools they need to quit – with proven treatment options like this, alongside specialist care, helping to save thousands of lives and the NHS millions of pounds in treatment costs.”

It is estimated that around one in eight adults in the UK smoke, totaling around six million people.

Smoking caused over 400,000 hospital admissions in England in 2022-23 and each year the NHS spends around £2.5 billion on treating health issues caused by smoking.

Varenicline works by reducing nicotine cravings, blocking its effect on the brain, and alleviating withdrawal symptoms such as irritability and difficulty sleeping.

The drug is being offered through NHS Stop Smoking Services, which smokers can access by self-referring via the NHS Better Health website.

Health secretary Wes Streeting remarked: “Prevention is better than cure. The rollout of this pill can save the NHS millions of pounds, save appointments to help other patients be seen faster, and save lives.”

“Taken alongside our tobacco and vapes bill, the government and NHS are building a healthy society to help power a healthy economy.”

Varenicline is being made available through a collaboration between NHS England and Teva UK.

The branded version of the drug, Champix, was withdrawn in 2021 due to an impurity. The new generic version has been approved as safe by the Medicines and Healthcare products Regulatory Agency (MHRA).

Research from University College London suggests that Varenicline could help over 85,000 people try to quit smoking each year and prevent up to 9,500 smoking-related deaths over the next five years.

A second smoking cessation drug, cytisine, is currently under review by the National Institute for Health and Care Excellence (NICE).

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less